EGFR and neoplasm: The 86Y-CHX-A’’-DTPA-panitumumab and 86Y-CHX-A’’-DTPA-cetuximab uptake in all the three tumor models was HER1-mediated as demonstrated by receptor-blocking experiments performed by co-injecting 0.1 mg of the corresponding unlabeled mAb (Fig. 1).